A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Thursday, 23 January 2014
AstraZeneca and Shanghai Institutes of Biological Sciences announce research collaboration SHANGHAI, CHINA – AstraZeneca today announced the signing of a research collaboration in the area of cardiovascular diseases (CVD) with the Shanghai Institutes of Biological Sciences (SIBS)
Tuesday, 3 December 2013
AstraZeneca and Lieber Institute for Brain Development announce neuroscience collaboration AstraZeneca today announced that it has entered into a two-year research collaboration with the Lieber Institute for Brain Development (LIBD) to use genetics and stem cell biology to discover new drugs for neuropsychiatric and neurodevelopmental disorders such as autism and schizophrenia.
Wednesday, 20 November 2013
Karolinska Institutet appoints Dr. Bo Angelin to lead integrated cardio metabolic center AstraZeneca and the Swedish medical university Karolinska Institutet announced today the appointment of Bo Angelin M.D. Ph.D. to lead their Integrated Cardio Metabolic Center (ICMC) located at the Karolinska Institutet site in Stockholm, Sweden.
Thursday, 14 November 2013
AstraZeneca announces initiation of two additional global studies for BRILINTA (ticagrelor) AstraZeneca today announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company’s largest clinical trial programme involving over 80,000 patients. The studies are designed to build scientific understanding of BRILINTA® (ticagrelor) tablets in additional high-risk patient populations.
Monday, 4 November 2013
A*STAR and AstraZeneca sign a research collaboration agreement to develop new antimicrobial drugs to combat Gram-negative bacterial infections Two units under Singapore’s Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Exploit Technologies Pte Ltd (ETPL) have signed a joint research collaboration agreement with global biopharmaceutical company AstraZeneca (AZ), to develop new drugs to treat Gram-negative bacterial infections. Such infections are believed to cause two thirds of all hospital acquired infection deaths.
Thursday, 17 October 2013
AstraZeneca announces ‘Open Innovation’ research collaboration with Taiwan’s research program for biopharmaceuticals AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) today announced a collaborative programme to support academic research proposals using ‘open innovation’ as a catalyst for drug discovery
Wednesday, 16 October 2013
Harvard's Wyss Institute and AstraZeneca Announce Collaboration on Organs-on-Chips for Drug Safety Testing Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and AstraZeneca announced a collaboration
Tuesday, 15 October 2013
TARIS® Biomedical Enters Research Collaboration with AstraZeneca TARIS Biomedical®, announced today that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer
Monday, 30 September 2013
AstraZeneca Oncology Update from European Cancer Congress in Amsterdam AstraZeneca and its global biologics research and development arm, MedImmune, presented oncology data at the European Cancer Congress (ECC) in Amsterdam this week (27 September – 1 October)
Tuesday, 10 September 2013
AstraZeneca and Hadasit announce drug discovery alliance AstraZeneca and Hadasit announce drug discovery alliance